Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

The FGFR inhibitors market is projected to witness substantial growth in the coming years, driven by the rising incidence of conditions such as urothelial carcinoma, cholangiocarcinoma, and ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

Clinical research is sine qua non for understanding and solving public health challenges.1 Clinical trials are central to advancing scientific knowledge and can have an impact on many areas (but not ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

Patent strengthens intellectual property for investigational new drug MTX-001 - Phase 2 clinical trial for chronic venous leg ulcers ongoing ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...